Pharmarise 2796.T closes JPY 517.00 on 18 Mar 2026: earnings spotlight ahead

2796.T stock jumped to JPY 517.00 at market close on 18 Mar 2026 as investors positioned ahead of an earnings release due 19 Mar 2026. Trading volume was 12,100 shares versus an average of 9,078, showing above-average attention. Pharmarise Holdings Corporation (JPX) runs dispensing pharmacies across Japan, and this earnings print will clarify near-term margins, dividend signals, and cash flow after a mixed 2025 financial year.

Earnings context for 2796.T stock

Pharmarise reports results on 19 Mar 2026; that announcement is the immediate catalyst for 2796.T stock. Market close price was JPY 517.00, up 1.17% on the day, with a day range of JPY 510.00–517.00. Recent coverage notes include Reuters and Investing.com for filings and calendar data; use these for official figures and timings Reuters and Investing.com.

Financials and valuation for 2796.T stock

Trailing metrics show EPS -13.00 and PE -39.62, signaling losses on a per-share basis for the last twelve months. Price-to-book is 0.86, with book value per share JPY 601.80. Debt-to-equity is 1.82, and current ratio is 1.02, indicating moderate leverage and tight liquidity ahead of results.

Meyka AI grade and technicals for 2796.T stock

Meyka AI rates 2796.T with a score out of 100: 68.54 (Grade B, suggestion: HOLD). This grade factors S&P 500 and sector comparison, growth, key metrics, forecasts, and analyst signals. Technicals show RSI 44.37, ADX 39.23, Bollinger middle JPY 513.75, and short-term momentum mixed. These indicators suggest range-bound trading into earnings.

Analyst view, price targets and forecasts for 2796.T stock

There is no broad sell-side consensus available publicly, so we frame targets from price history and Meyka AI modelling. Current price JPY 517.00 sits below the year high JPY 567.00 and above the year low JPY 456.00. Suggested price targets: conservative JPY 480.00, base JPY 530.00, bullish JPY 600.00, reflecting scenario outcomes for margin recovery and same-store sales.

Risks and opportunities for 2796.T stock

Primary risks include operating losses, leverage and weaker cash flow; net income margin is negative at -0.21%. Opportunities are stable retail demand for dispensing pharmacies, a JPY 14.00 dividend per share history, and a low price-to-sales of 0.09 that limits downside if cash flows recover. Watch guidance and store-level metrics in the earnings release.

Trading note and sector comparison for 2796.T stock

Healthcare peers trade at an average PE 23.62, while Pharmarise is loss-making and trades at PB 0.86 versus the sector PB 1.21. Volume and volatility typically rise on earnings day; average volume is 9,078, today’s 12,100 signals active position-taking. Use tight risk controls and watch JPX post-close commentary.

Final Thoughts

Key takeaway: 2796.T stock closed at JPY 517.00 on 18 Mar 2026 as the market priced an imminent earnings release. Meyka AI’s forecast model projects a yearly price of JPY 444.76, implying -13.98% downside versus today’s close; forecasts are model-based projections and not guarantees. Our Meyka AI grade of 68.54 (B, HOLD) reflects mixed fundamentals: low valuation ratios like PB 0.86 and P/S 0.09, offset by negative net income and higher debt-to-equity 1.82. For traders, the earnings print will determine near-term direction; for longer-term investors, watch free cash flow recovery, dividend sustainability, and whether management narrows leverage. Meyka AI provides this as AI-powered market analysis and not as investment advice

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.